Taken together, our data suggest that CAPRIN1 knockdown might confer sensitivity to cisplatin and rapamycin in NPC cells, which may be useful for the clinical application of CAPRIN1 as a target in drug combinations. Here, CAPRIN1 is linked to nasopharyngeal carcinoma.